
On August 15, 2025, the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research issued a warning letter to Innate Healthcare Institute in Scottsdale, Arizona. The letter was directed to founder and Chief Medical Officer Travis Whitney, NMD, after a review of the clinic’s website.
The agency examined marketing of umbilical cord mesenchymal stem cells (UC-MSCs), also referred to as UC-MSC therapy, for allogeneic use. Website content reviewed by the FDA included statements about treating autism “at its root,” patient comments suggesting benefits for a child with autism, and descriptions of the cells modulating immune responses and supporting regeneration.
Additional language listed potential applications for osteoarthritis, degenerative disc disease, COPD, autoimmune conditions, heart disease, and other health issues.
The FDA determined that these intended uses classify the product as a drug under the Federal Food, Drug, and Cosmetic Act and a biological product under the Public Health Service Act.
According to the letter, the product did not meet the criteria to be regulated solely as a human cell, tissue, or cellular or tissue-based product. Specifically, the processing was found not to satisfy the minimal manipulation standard, and the FDA said intended uses went beyond homologous use.
Without an approved biologics license application, a product cannot lawfully be marketed for these purposes in interstate commerce. The agency also noted that the product was misbranded because it lacked adequate directions for safe use by a layperson.
The Innate Healthcare letter referenced marketing of exosomes as well and pointed to the FDA’s existing public safety notification on such products. Innate Healthcare Institute was given 15 working days to respond with corrective steps.
This investigation has not made any determination as to the legality of any clinic's business practice, and Innate Healthcare Institute has admitted no wrongdoing.
This warning letter illustrates a core principle for regenerative medicine providers in that marketing materials must accurately reflect the current regulatory and scientific status of the therapies offered.
When language suggests treatment or improvement of specific diseases without the required FDA pathway, patients may develop expectations that exceed available evidence.
Clear, non-misleading communications support informed decision-making. Patients and families deserve accurate information about regulatory status, the investigational nature of many cellular products, and the absence of FDA approval for most orthopedic or autoimmune indications.
Transparency reduces the chance of misunderstanding and helps protect individuals who often face significant financial and emotional considerations when exploring regenerative options.
Avoiding overstated or disease-treatment claims helps maintain trust in the regenerative field as a whole. Accurate descriptions of services, limitations, and evidence levels allow clinics to communicate responsibly while still educating the public. Precise language remains essential for ethical patient care and long-term industry credibility.
Clinics that prioritize transparency on their websites and promotional materials better align with regulatory expectations and support patients in making well-informed choices. Our lawyers ensure that the consumer is protected in this regard.
If you or a loved one received stem cell or regenerative therapy at Innate Healthcare Institute and have questions about the marketing claims involved, The Lyon Firm is investigating stem cell clinics and has filed related consumer fraud class actions. Contact our team for a free case evaluation.
Taking the first step doesn’t have to be complicated. In just a few minutes, you can share the basics of your case, and our team will guide you from there: